Novartis AG (NOVN.VX)

NOVN.VX on Virt-X Level 1

66.60CHF
31 Jul 2013
Price Change (% chg)

CHF0.35 (+0.53%)
Prev Close
CHF66.25
Open
CHF66.00
Day's High
CHF66.95
Day's Low
CHF65.70
Volume
3,633,507
Avg. Vol
4,192,321
52-wk High
CHF73.75
52-wk Low
CHF55.20

NOVN.VX

Chart for NOVN.VX

About

Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and... (more)

Overall

Beta: 0.79
Market Cap (Mil.): CHF179,553.91
Shares Outstanding (Mil.): 2,706.19
Dividend: 2.30
Yield (%): 3.45

Financials

  NOVN.VX Industry Sector
P/E (TTM): 18.91 37.93 37.76
EPS (TTM): 3.51 -- --
ROI: 10.03 19.48 18.76
ROE: 14.08 20.17 19.59
Search Stocks

Patient taking Novartis MS pill developed rare disease

ZURICH - A patient taking Novartis' multiple sclerosis pill Gilenya developed a rare and potentially fatal viral disease, the Swiss drugmaker said on Tuesday, an unexpected setback as it faces growing competition from new oral treatments.

30 Jul 2013

U.S. court permits generic version of Teva MS drug a year sooner

WASHINGTON/NEW YORK - Teva Pharmaceutical Industries' $4 billion-a-year multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court on Friday, making it potentially prey to cheaper generics next May.

26 Jul 2013

UPDATE 1-US court permits generic version of Teva MS drug a year sooner

WASHINGTON/NEW YORK, July 26 - Teva Pharmaceutical Industries' $4 billion-a-year multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court on Friday, making it potentially prey to cheaper generics next May.

26 Jul 2013

Europe backs new dual-action Novartis lung drug

LONDON - Swiss drugmaker Novartis won an important endorsement of its new inhaled medicine for chronic lung disease on Friday when European regulators recommended approval of Ultibro Breezhaler.

26 Jul 2013

UPDATE 2-Europe backs new dual-action Novartis lung drug

LONDON, July 26 - Swiss drugmaker Novartis won an important endorsement of its new inhaled medicine for chronic lung disease on Friday when European regulators recommended approval of Ultibro Breezhaler.

26 Jul 2013

EU regulators back Novartis inhaler, Gilead HIV drug

LONDON, July 26 - European regulators on Friday recommended approval of a new once-daily inhaler for lung disease from Novartis and an HIV medicine from Gilead Sciences.

26 Jul 2013

Novartis vaccine division hit by Bexsero setback

ZURICH - Swiss drugmaker Novartis suffered a fresh blow to the turnaround prospects of its loss-making vaccines division as a key committee advised against including its meningitis B vaccine on Britain's routine vaccination program.

24 Jul 2013

Novartis vaccine division hit by Bexsero setback

* UK committee advises against inclusion in vaccine programme

24 Jul 2013

Novartis lifts full-year outlook after competition delay

ZURICH - Novartis raised its full-year outlook on Wednesday after generic competition to its best-selling blood pressure pill was delayed, granting the Swiss drugmaker a temporary reprieve from patent losses. | Video

17 Jul 2013

UPDATE 2-Novartis lifts full-year outlook after competition delay

* Q2 core EPS down 4 pct at $1.30 vs $1.34 in Reuters poll

17 Jul 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$495.00
Provider: Plunkett Research, Ltd.
$99.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks